Consent Cover Page 
 
Official Title of the Study: Project Q Pi[INVESTIGATOR_2268]: Smoking Cessa tion for Light Smokers  
Study ID: [REMOVED]  
Date IRB Approved: 1/17/[ADDRESS_242597] udy staff discusses this 
consent form with you, please ask him/her to explain any words or information that you do not clearly 
understand. We encourage you to talk with your family a nd friends before you decide to take part in this 
research study. The nature of the study, risks, inconveniences, discomforts, and other important 
information about the study are listed below. 
 
Please tell study staff if you are taki ng part in another research study. 
 
[CONTACT_203351] will conduct the study and it is funded by [CONTACT_203344]. Portions of [CONTACT_203352]’s research team’s sa laries will be paid  by [CONTACT_68793]. 
 
WHY IS THIS STUDY BEING DONE? 
The purpose of this study is to test whether people find a new program helpful as they attempt to quit 
smoking. The study includes counseling and texti ng about your smoking and cravings to smoke. 
 
HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY? 
Approximately 30 people will complete this study at Duke. 
 
WHAT IS INVOLVED IN THE STUDY? 
If you agree to be in this study, you will be asked to sign and date this consent form. To make sure the 
study is right for you, you will be asked to answer 
 Questions on the following: how often you smoke, use of other tobacco products, depression, 
anxiety, drug and alcohol use, wi llingness to attend all study visits. 
 
Depending on the results of the questions, you may not be eligible for the study. 
 
 
DUHS IRB 
IRB NUMBER: Pro00089760 
IRB REFERENCE DATE: 01/17/2020 
IRB EXPI[INVESTIGATOR_2352]: 02/01/[ADDRESS_242598] Q Pi[INVESTIGATOR_203341]: If you sign the consent and pass scre ening criteria, you may be in the 
study. If you are in the study, we will assign you ( like flippi[INVESTIGATOR_007] a coin) to one of two groups.  
 
We will ask you to pi[INVESTIGATOR_9696] a smoking quit date that is about one week afte r your first study visit (today). 
Also, we will ask you to attend up to six study visits (i ncluding today’s visit), ea ch lasting about 1 to 1.5 
hours. 
 
 Study Visit [ADDRESS_242599]  for a chemical called carbon monoxide, which comes 
from smoking cigarettes. We also will ask you to  talk to our study staff about your smoking and 
make plans to try to quit. We will provide instructions on how to send us text messages to help us learn about your smoking. We will ask you to pi [INVESTIGATOR_9696] a quit date that is within 1-2 weeks. 
 Real time smoking data collection . (Second group only) After Study Visit 1, we will ask that 
you text us every time you smoke for 4 days. We  will ask you a few questions about what is 
going on for you when you are smoking. We will also  ask you to take a pi[INVESTIGATOR_203342] 4 days. 
 Study Visit [ADDRESS_242600] related to smoking, as well as other items that may remind you of smoking (such as cigarettes, a lighter, etc.). You will not be able to smoke while viewing 
the photos or holding these objects. We w ill ask you to answer questions about your 
desire to smoke afterwards. 
 Between Visit 2 and Visit 3: We will send you one or two text messages a day to help you not 
smoke. We will also ask you to text the study wh en you are craving a cigarette or if you smoke 
and the study will text you to help you not smok e at that time and to ask you questions about 
craving and stress level. 
 Study Visit [ADDRESS_242601] related to smoking, as well as, other physical items that may remind you 
of smoking (i.e. cigarettes, a lighter, etc.). You will not be able to smoke while viewing 
the photos or holding these objects. We w ill ask you to answer questions about your 
desire to smoke afterwards. 
 Between Visit 3 and Visit 4. We will send you one or two text messages a day to help you not 
smoke. If you are assigned to the second group, you will be asked to text the study when you are craving a cigarette or if you smoke and the study w ill text you to help you not smoke at that time 
and to ask you questions about  craving and stress level. 
 Study Visit 4 will occur approximately1 week after Vi sit 3. We will ask you to answer a few 
questions about your smoking and pr ovide another breath sample. 
DUHS IRB 
IRB NUMBER: Pro00089760 IRB REFERENCE DATE: 01/17/2020 
IRB EXPI[INVESTIGATOR_2352]: 02/01/[ADDRESS_242602]  related to smoking, as well as, other 
physical items that may remind you of smoking (i .e. cigarettes, a light er, etc.). You will 
not be able to smoke while viewing the phot os or holding these objects. We will ask you 
to answer questions about your desire to smoke afterwards. 
 Between Visit 4 and Visit 5 (Second group only) . We will send you one or two text messages a 
day to help you not smoke. If you are assigned to  the second group, you will be asked to text the 
study when you are craving a cigarette or if you smoke and the study will text you to help you 
not smoke at that time and to ask you que stions about cravi ng and stress level. 
 Study Visit [ADDRESS_242603] related to smoking, as well as, other physical items that may remind you 
of smoking (i.e. cigarettes, a lighter, etc.). You will not be able to smoke while viewing 
the photos or holding these objects. We w ill ask you to answer questions about your 
desire to smoke afterwards. 
 Between Visit 5 and Visit 6 (Second group only). We will send you one or two text messages a 
day to help you not smoke. If you are assigned to  the second group, you will be asked to text the 
study when you are craving a cigarette or if you smoke and the study will text you to help you 
not smoke at that time and to ask you que stions about cravi ng and stress level. 
 Visit [ADDRESS_242604] your ability to participate in this study. 
 
HOW LONG WILL I BE IN THIS STUDY? 
Your entire study participati on, including follow-up, will last approximately 7 weeks. 
 
WHAT ARE THE RISKS OF THE STUDY? 
 
 
DUHS IRB 
IRB NUMBER: Pro00089760 
IRB REFERENCE DATE: 01/17/2020 
IRB EXPI[INVESTIGATOR_2352]: 02/01/[ADDRESS_242605] Q Pi[INVESTIGATOR_203343]. Every effort will  be made to keep your information 
confidential; however, this cannot be guaranteed. Some of  the questions we will ask you as part of this  
study may make you feel uncomfortable. You may refuse  to answer any of the questions and you may 
take a break at any time during the study. You may stop your participa tion in this study at any time. 
 
As a result of your participation in  this study, you are at risk for the side effects described below. You 
should discuss these side effects w ith the study doctor or physician as sistant, as well as your regular 
health care provider if you choose. 
 
Smoking Withdrawal: 
When quitting smoking you may experience some, all or  none of the withdrawal symptoms: headache, 
nausea, constipation or diarrhea, decrease in heart rate and blood pressure, fatigue, drowsiness, and 
insomnia, irritability, difficulty concentrating, anxiet y, depression, tobacco cravi ngs, increased desire for 
the taste of sweets, and/or increased hunger and caloric intake leading to weight gain. 
 
ARE THERE BENEFITS TO TAKI NG PART IN THE STUDY? 
If you agree to take part in this  study, there may be direct medical  benefit to you. A possible benefit 
from participation in this study is quitting smoking. We  hope that in the future the information learned 
from this study will benefit people that smoke in the future. 
 
WHAT ALTERNATIVES ARE THERE TO PARTICIPATION IN THIS STUDY? 
If you do not wish to participate in this study, there are othe r alternatives to treat  tobacco use. You can 
talk with your doctor about pres cription medicines that may help you quit (including Varenicline or 
Bupropi[INVESTIGATOR_2394]), or nicotine-replacement products offered out side of this study, both over-the-counter and by 
[CONTACT_50246]. Information about these resources is  available through the No rth Carolina Tobacco Use 
Quit line at http://www.quitnownc.o rg or by [CONTACT_3379] ([PHONE_4376]. 
 
WILL MY INFORMATION BE KEPT CONFIDENTIAL? 
Participation in research can invol ve some loss of privacy. We will do our best to make sure that 
information about you is kept confidential, but we cannot guarantee total conf identiality. Your personal 
information may be viewed by [CONTACT_203345], funding, and regul ating the study. We will share only the minimum 
necessary information to conduct th e research. Your personal informa tion may also be given out if 
required by [CONTACT_2371]. 
 
The texting gateway system used for delivering the text messages to and from your cell phone will store 
the phone number you use for sending and receiving messages, along with the content of the text 
messages you will receive or send. These messages will only be about your smoking. The texting system 
will be managed by [CONTACT_203346], NC. Once the study is over, we will destroy all text 
messages. 
 
In addition, your records may be reviewed to meet federal or state regulati ons. Reviewers may include 
the Duke Cancer Institute, the Duke  University Health System Institu tional Review Board, and others as 
appropriate. If any of these groups review your research r ecord, they may also need to review your 
entire medical record. 
 
DUHS IRB 
IRB NUMBER: Pro00089760 
IRB REFERENCE DATE: 01/17/2020 
IRB EXPI[INVESTIGATOR_2352]: 02/01/[ADDRESS_242606] 
shared. Other laws may or may not protec t sharing of private health information. 
 
A description of this clinical  trial will be available on http://www.ClinicalTrials.gov , as required by U.S. 
Law. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You can  search this Web site at any time.  
 
WHAT ARE THE COSTS TO YOU? 
There will be no additional costs to  you as a result of being in this st udy. However, routine medical care 
you would have received whether or not you were in th is study will be charged to you or your insurance 
company. You may wish to contact [CONTACT_203347]. We will monitor 
your DUHS patient care charges to make sure that costs are direct ed appropriately. If you have any 
questions or concerns about  appropriate billing, cont act your study team coordina tor so that he/she can 
help find a resolution. These tests an d studies are not a part of routin e care, and people who are not part 
of the study do not usually have them performed. Pl ease ask [CONTACT_160759] or th e study staff if you would 
like to know more about which te sts and studies are being done solely for research purposes. 
 
WHAT ABOUT COMPENSATION? 
You will be reimbursed up to $150 for your expenses related to your participation (parking, gas, and 
time). You will receive $50 for completing Visit 1. You will be compensated $100 at your final visit 
(either Visit 4 or Visit 6 depe nding on which group you are in). 
 
WHAT ABOUT RESEARCH RELATED INJURIES? 
Immediate necessary medical care is available at Duke University Medi cal Center in the event that you 
are injured as a result of your part icipation in this research study. However, there is no commitment by 
 
[CONTACT_203348]: Pro00089760 
IRB REFERENCE DATE: 01/17/2020 
IRB EXPI[INVESTIGATOR_2352]: 02/01/[ADDRESS_242607]. Kathryn Pollak at ([PHONE_3556] or 
the study coordinator, Shayna Clancy at (919) [ADDRESS_242608]. Pollak at 
([PHONE_3557] after hours and on w eekends and holidays. You can reach [CONTACT_33696], the study 
doctor, 24-hours a day at ([PHONE_4377]. 
 
WHAT ABOUT MY RIGHTS TO DECLINE P ARTICIPATION OR WITHDRAW FROM THE 
STUDY? 
Being in this trial is voluntary. If you do not sign this consent form, you will continue to receive care, 
but not as part of this study. You may choose not to be in the study, or , if you agree to be in the study, 
you may withdraw from the study at any time. However,  if you decide to stop pa rticipating in the study, 
we encourage you to talk to study staff first. If you withdraw from the study, no new data about you will 
be collected for study purposes unless the data concern an adverse even t (a bad effect) related to the 
study. If such an adverse event occurs, we ma y need to review your entire medical record. 
 
Your decision not to participate or to withdraw from  the study will not involve any penalty or loss of 
benefits to which you are entitled, and will not a ffect your access to health care at Duke. If you do 
decide to withdraw, we ask th at you contact [INVESTIGATOR_124]. Pollak in writi ng and let her know that you are 
withdrawing from the study. Her mailing addres s is [ADDRESS_242609] the ability 
to evaluate the study endpoints or any new information becomes available during the study that 
necessitates stoppi[INVESTIGATOR_10098]. If this occurs, you w ill be notified and your study doctor will discuss 
other options with you. 
 
Your samples and/or data may be stored and shared  for future research without additional informed 
consent if identifiable private info rmation, such as your name [CONTACT_39650], are removed. 
If your identifying information is removed from your  samples or data, we will no longer be able to 
identify and destroy them. 
 
The use of your samples may result in commercial profit. You will not be compensated for the use of your samples other than what is described in this consent form. 
A description of this clinical  trial will be available on https://clinicaltrials.gov/ as required by U.S. Law 
(Study Registry ID: [REMOVED]). This Web site will not include information that can 
identify you. At most, the Web site will include a summ ary of the results. You can search this Web site 
at any time. 
 
 
DUHS IRB 
IRB NUMBER: Pro00089760 
IRB REFERENCE DATE: 01/17/2020 
IRB EXPI[INVESTIGATOR_2352]: 02/01/[ADDRESS_242610] QUESTIONS OR PROBLEMS? 
For questions about the study or a re search-related injury, or if you ha ve problems, concerns, questions 
or suggestions about the researc h, contact [INVESTIGATOR_124]. Kathryn Pollak at ([PHONE_3556] during regular business 
hours and [CONTACT_160759] at ([PHONE_3557] afte r hours and on weekends and holidays. 
 
For questions about your rights as a research participan t, or to discuss problems , concerns or suggestions 
related to the research, or to obt ain information or offer input about  the research, contact [CONTACT_203349] (IRB) Office at ([PHONE_1921]. STATEMENT 
OF CONSENT 
"The purpose of this study, procedures  to be followed, risks and benef its have been explained to me. I 
have been allowed to ask questions, and my questions  have been answered to  my satisfaction. I have 
been told whom to contact [CONTACT_39646] I ha ve questions, to discuss problems, c oncerns, or suggestions related to 
the research, or to obtain information or offer input a bout the research. I have r ead this consent form and 
agree to be in this study, with the understanding that I may withdraw at any time. I have been told that I 
will be given a signed and dated copy of this consent form." 
 
 
Signature [CONTACT_203350]: Pro00089760 
IRB REFERENCE DATE: 01/17/2020 
IRB EXPI[INVESTIGATOR_2352]: 02/01/2021  
 
Page 7 of 7 